Manufacturer or GPO Program year 2021 Source: CMS Open Payments

Innate Pharma, Inc

MD, United States

CMS manufacturer 100000791824

Open in the dashboard

General payments

$72,350

129 payments

Research payments

$3,258,304

170 payments

Ownership & investment interest

$0

None reported

Through program year 2021, Innate Pharma, Inc reported paying $72,350 in general payments and $3,258,304 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2021 General $21,712 8
2021 Research $150,989 20
2020 General $50,638 121
2020 Research $3,107,315 150

Breakdown

Top recipients General payments · program year 2021
  1. Mario Sznol Medical Oncology · New Haven, CT $7,920 1 payment
  2. James Blachly Hematology · Columbus, OH $4,200 1 payment
  3. Tanguy Lim-Seiwert Medical Oncology · Baltimore, MD $3,960 1 payment
  4. Pierluigi Porcu Hematology & Oncology · Philadelphia, PA $3,900 1 payment
  5. Leslie Oleksowicz Medical Oncology · Cincinnati, OH $550 1 payment
  6. Oleg Akilov Dermatology · Pittsburgh, PA $483 1 payment
  7. Nam Dang Medical Oncology · Gainesville, FL $358 1 payment
  8. Eric Jacobsen Hematology & Oncology · Boston, MA $340 1 payment
Top research recipients Research payments · program year 2021
  1. Thomas Marron Medical Oncology · New York, NY $41,453 6 payments
  2. Anthony Tolcher Medical Oncology · San Antonio, TX $38,453 6 payments
  3. David Hsieh Medical Oncology · Dallas, TX $38,118 1 payment
  4. Vivek Sharma Hematology & Oncology · Louisville, KY $14,965 2 payments
  5. Dylan Zylla Internal Medicine · Saint Louis Park, MN $10,500 3 payments
  6. Johanna Bendell Hematology & Oncology · Nashville, TN $7,500 2 payments
Products the payments named General payments · program year 2021
  1. Lumoxiti Oncology $21,712 100% · 8 recipients

Each share is of this company’s general payments naming a product in 2021. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2021
  1. Medical Oncology Internal Medicine $12,788 59% · 4 practitioners
  2. Hematology & Oncology Internal Medicine $4,240 20% · 2 practitioners
  3. Hematology Internal Medicine $4,200 19% · 1 practitioner
  4. Dermatology $483 2% · 1 practitioner

Each share is of this company’s general payments to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2021
  1. Connecticut $7,920 36% · 1 recipient
  2. Ohio $4,750 22% · 2 recipients
  3. Pennsylvania $4,383 20% · 2 recipients
  4. Illinois $3,960 18% · 1 recipient
  5. Florida $358 2% · 1 recipient

The top 5 of 6 states; each share is of this company’s general payments in 2021 where a state was reported.

The top 25 states, free in the app

What the payments were for General payments · program years 2020–2021
  1. Honoraria $39,750 20 payments
  2. Consulting Fee $29,136 9 payments
  3. Food and Beverage $3,464 100 payments
129 general · 170 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record